Sabater, L, Guasp, M, García, RR, Rondán, LN, Querol, L, Martín-Aguilar, L, Llarch, P, Balasa, M, Lladó, A, Painous, C, Compta, Y, Serafim, AB, Montini, A, Iranzo, A, Cano, JS, Dalmau, JO, Graus, F, Gaig, C. Prognostic Determinants of Presentation and Outcome in Anti-IgLON5 Disease. Neurology-Neuroimmunology & Neuroinflammation. 2026; 13(4)DOI:10.1212/NXI.0000000000200600. PMID:42241645. IF:7.500(Q1/1D).

Pena-Guzman, L, Bolano-Díaz, C, Lleixà, C, Querol, L, Trainor, C, Suetterlin, K, Straub, V, Díaz-Manera, J. Sensory neuronopathy secondary to gene therapy with AT845 for Pompe disease. NEUROMUSCULAR DISORDERS. 2026; 64DOI:10.1016/j.nmd.2026.106441. PMID:42142433. IF:2.800(Q2/5D).

Putri, VP, Samarasekera, N, Moullaali, TJ, Jampana, S, Aked, J, Åsberg, S, Schulman, S, Tsivgoulis, G, Pikilidou, M, Tsai, HH, Tsai, LK, Myint, PK, Pana, TA, Cordonnier, C, Casolla, B, Gaist, D, Pezzini, A, Camps-Renom, P, Klijn, CJM, Romoli, M, Tveiten, A, Liu, M, Xu, MM, Wu, B, Werring, D, Nash, PS, Banerjee, G, Li, LX, Salman, RAS. Rates and risk factors for major adverse cardiovascular and cerebrovascular events after stroke due to intracerebral hemorrhage: Systematic review and study-level meta-analysis. International Journal of Stroke. 2026; 21(6)DOI:10.1177/17474930261416692. PMID:41605872. IF:8.700(Q1/1D).

Majem, M, Mata, KM, Ibarguren, AM, Poves, MZ, Requena, C, Aparisi, FDA, Carrera, C, Cordellat, AB, Freites-Martinez, A, Sanmartin, O. Diagnosis and treatment of cutaneous adverse effects of targeted therapy, antibody-drug conjugates, and immunotherapy in cancer patients: a national consensus statement by the Spanish Society of Medical Oncology and the Spanish Academy of Dermatology and Venereology. Clinical & Translational Oncology. 2026; 28(7)DOI:10.1007/s12094-025-04209-0. PMID:41604110. IF:2.500(Q3/6D).